News | October 30, 2023
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
The extension builds upon an existing long-term collaboration for end-to-end ADC manufacturing, including payload, monoclonal antibody (mAb) manufacturing and bioconjugation
His M&A background and experience with successful private-equity-backed companies will benefit the company’s growth and diversification strategy
Capital raise to accelerate product and technology development and support expansion efforts to reshape communications to HCPs across the globe
The AGE1.CR.pIX cell line's versatility allows it to support a wide range of viruses and vaccine types
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Approval of this product under the PEPFAR program completes Strides’ qualification to all major markets and donor programs including Global Fund and South Africa
Subscribe To Our Newsletter & Stay Updated
